Mandate

Vinge has advised XVIVO in conjunction with its directed share issue of SEK 440 million.

September 14, 2023 M&A

Vinge has advised XVIVO Perfusion AB in connection with its directed share issue at a subscription price of SEK 275 per share which corresponded to the closing price of XVIVO’s shares on Nasdaq Stockholm on the day of the issue.

XVIVO received SEK 440 million before issue costs. The subscription price was determined through an accelerated bookbuilding procedure arranged by Carnegie and DNB Markets. Investors in the directed share issue were both existing and new shareholders such as Bure Equity AB, the Fourth Swedish National Pension Fund, Swedbank Robur Fonder, Eccenovo, Handelsbanken Fonder, Tredje AP-fonden and a Tier-1 global international investor.

Vinge's team primarily consisted of Anders Strid and project manager Edin Agic.

 

Related

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025